PRIMARY ENDPOINT
55%
ORR (BICR-confirmed)
Naïve 50% · Treated 60%
Our pipeline
Abion’s drug discovery begins with the biological mechanisms that enable cancer to evade existing therapies and develop resistance.
Building on this understanding, we deploy four therapeutic modalities—small molecules, antibodies, bispecific antibodies, and antibody–cytokine fusions—to address c-MET–mediated resistance to targeted therapies, Claudin-3 as a historically difficult-to-drug antibody target, and acquired resistance and limited durability of response to TROP2-directed ADCs. Each program is designed from the early stages of development alongside a biomarker strategy to identify patients most likely to benefit.
Program
Target
Modality
Lead indication
Stage
ABN202 TROP2(iRAC platform) IRACAntibody–interferon-β fusion Solid tumors after ADC failure
ABN202
The lead iRAC candidate — a TROP2-directed antibody fused to interferon-β, designed for tumours that have progressed on ADC therapy.
- Overcoming the Limitations of ADCs
- Novel Mechanism of Action
- Validation of Preclinical Findings
- Validation of the Development Plan Through IND
ABN501 Claudin-3(CLDN3) CLDN3Human monoclonal antibody, with ADC and bispecific formats CLDN3-positive solid tumors including SCLC
ABN501
A first-in-class human antibody against claudin-3, a tight-junction protein overexpressed across solid tumours.
- Why CLDN3 Has Historically Been Overlooked
- Antibody characteristics and selectivity
- Monoclonal Antibody, ADC, and CLDN3×CD3 Bispecific Antibody
- Potential for Indication Expansion
ABN401Vabametkib c-MET Small moleculeOral small-molecule TKI NSCLC with MET exon 14 skipping or MET amplification
Vabametkib (ABN401)
An oral, selective c-MET inhibitor in Phase 2 for NSCLC driven by MET exon 14 skipping and MET amplification.
- Challenges associated with c-MET
- Differentiating features of Vabametkib (selectivity, tolerability)
- Clinical program highlights
- Concurrent development of companion diagnostics
DISEASE CONTROL
83%
DCR vs. ~80% for approved peers
PROGRESSION-FREE
8.54mo
median PFS tepo 8.5 · cap 6.7 · savo 6.9
DURABILITY ★
19.4mo
median DoR (naïve) — longest reported in class
Technology (iRAC platform)
iRAC — interferon-β, delivered where it matters.
While conventional interferons activate immune responses and relevant systemic toxicity, But Abion’s iRAC targets the tumor specifically, increasing signals exclusively within the tumor itself
- Target-selective
- Novel dual mechanism
- Preclinical data validation complete
- Clinical strategy established
